Baker McKenzie advised Galapagos on its intended separation into two publicly traded entities. Through the separation, Galapagos will create a new entity with a cash position of approximately EUR 2.45 billion, dedicated to building a pipeline of innovative medicines through strategic transactions. Galapagos will continue its focus on accelerating cell therapies and building a global decentralised manufacturing network. As part of the strategic reorganization, Galapagos will discontinue its small molecule discovery programs and seek partners for these assets. The separation is expected to be completed by mid-2025. This strategic move aims to unlock shareholder value and position both entities for long-term growth and innovation.
The Baker McKenzie team was led by corporate finance partner Roel Meers (Brussels) and included partners Oren Livne (New York), Michael Van Acker (Brussels), Julia Schieber (Zurich), Glenn Woll (New York), Davinia Martens (Brussels), Adam Farlow (London), and Creighton Macy (Washinton, DC), and several counsel and associates, including notably Ines Silvestrini (Brussels), Veerle Lerut (Brussels), Elvin Lawson (Brussels), Alexander Gee (London), Ryan Howlett (London), and Dukki Moon (Washington, DC).
Talking about this transaction, lead Partner Roel Meers said: “This separation marks a pivotal moment in Galapagos’s journey. We are pleased to have played a part in setting the stage for sustained growth and innovation within the biotech sector.”
The deal is representative of the breadth and depth of Baker McKenzie's cross-border experience advising healthcare and life sciences companies on their most business critical transactions. As one of the first law firms to advise life sciences corporates on their global expansion 60 years ago, the Firm's knowledge is rooted in its DNA, with more than 800 dedicated lawyers focused on the sector in more than 45 jurisdictions, including the 10 largest life sciences markets globally.
Baker McKenzie is a transactional powerhouse, with more than 2,500 deal practitioners in 45 jurisdictions offering leading expertise in the areas most critical for our clients. The Firm excels in complex transactions and cross-border deals – over 65% of our deals are multi-jurisdictional.
Learn more on Galapagos website: Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities - Galapagos